Hemostasis Valve Market Size, Share & Trends Analysis Report By Type, By Application (Angiography, Angioplasty), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Hemostasis Valve Market Size & Trends

The global hemostasis valve market size was estimated at USD 174.8 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030. The increasing prevalence of cardiovascular diseases, supportive regulatory frameworks, rising geriatric population, and technological advancements are significantly driving the market growth. According to the report published by World Heart Federation in 2023, cardiovascular diseases (CVDs) have a profound global impact, affecting over half a billion people worldwide and resulting in approximately 20.5 million deaths in 2021.This, in turn, drives the demand for diagnostic and therapeutic procedures like angiography and angioplasty, where hemostasis valves are essential to ensure patient safety by controlling blood flow during catheterization procedures.

The growing preference for minimally invasive procedures is another significant factor propelling the market growth. Minimally invasive techniques offer numerous benefits over traditional open surgeries, including reduced pain, shorter hospital stays, faster recovery times, and lower risk of complications. As a result, there is a heightened demand for medical devices that facilitate these procedures. Hemostasis valves are integral to minimally invasive catheter-based interventions, as they enable precise control of blood flow and prevent leakage during the procedure. The shift towards minimally invasive techniques in cardiology and other medical fields drives the adoption of hemostasis valves.

The global demographic landscape is undergoing a notable shift towards aging, driven by declining birth rates and advancements in healthcare that have prolonged life expectancy. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion globally. This demographic transition underscores the increasing prevalence of age-related conditions, including cardiovascular diseases (CVDs) among older adults. According to the article published by the American Heart Association in November 2023, heart failure is a widespread and multifaceted cardiovascular condition impacting more than 6.7 million Americans, particularly prevalent among individuals aged 65 and older. The aging population is susceptibility to cardiovascular diseases drive the demand for diagnostic and therapeutic procedures, driving the market growth.

Technological advancements in medical devices are pivotal in driving the market growth. Materials, design, and functionality innovations have developed more effective and reliable hemostasis valves. For instance, using advanced polymers and coatings has improved the durability and biocompatibility of these devices, reducing complications such as thrombosis and infection. In addition, incorporating novel features such as easy-to-use locking mechanisms and enhanced sealing capabilities has increased the efficiency of hemostasis valves in clinical settings. For instance, the WATCHDOG Hemostasis Valve by Boston Scientific Corporation incorporates an innovative cross-slit design to minimize leakage, complemented by an 8F inner lumen that simultaneously accommodates multiple devices. In addition, it includes a thumb rest feature designed for enhanced comfort during procedures. The design elements collectively contribute to reducing blood loss and the risk of air embolism, prioritizing patient safety throughout medical interventions. These technological improvements ensure that procedures are safer and more efficient, boosting the adoption of hemostasis valves.

Type Insights

Based on type, the hemostasis valve y-connectors segment held the largest market share of 37.27% in 2023, owing to their versatile functionality, extensive clinical adoption, and pivotal role in enhancing patient outcomes during minimally invasive procedures. Their ability to facilitate multiple device manipulations while maintaining hemostasis and their proven reliability and ongoing innovations ensure their dominant position in the global market. For instance, OKAY II by Nipro is a hemostatic connector designed to minimize blood loss during medical procedures effectively. Its spacious 3.33mm inner diameter accommodates a wide range of Percutaneous Coronary Intervention (PCI) devices and techniques, ensuring versatility and compatibility in clinical settings. As the demand for minimally invasive cardiovascular interventions continues to rise, the importance and utilization of Y-connectors are expected to grow, further reinforcing their market leadership.

The one-handed hemostasis valve segment is expected to grow at the fastest CAGR of 6.6% during the forecast period. This growth is attributed to their ergonomic design, technological advancements, and expanding applications. Traditional hemostasis valves require two hands to operate, making them cumbersome and time-consuming. One-handed hemostasis valves allow clinicians to control blood flow and manage catheters with a single hand, freeing the other hand for additional tasks. Their versatility across various medical fields, such as interventional radiology, neurology, and gastroenterology, further boosts their market potential and drives growth.

Application Insights

Based on application, the angiography segment led the market with the largest revenue share of 64.16% in 2023 and is also expected to grow at the fastest CAGR of 6.2% during the forecast period. This predominance is primarily attributed to the rising number of angiographic procedures performed globally. According to the article published by the National Library of Medicine in September 2023, coronary angiography (CAG) is the gold standard for diagnosing obstructive coronary artery disease (CAD). Approximately 4 million angiograms are annually performed across Europe and the U.S., underscoring its critical role in cardiovascular care. This advanced imaging technique allows for precise visualization of coronary arteries, aiding in identifying significant blockages.

The angioplasty segment is also expected to grow at a significant CAGR during the forecast period. According to Eurostat, in 2021, 1.1 million transluminal coronary angioplasty procedures were performed across 25 European Union countries. The increasing prevalence of cardiovascular diseases, technological advancements, a shift towards minimally invasive procedures, the expansion of healthcare infrastructure in emerging economies, and rising awareness about early diagnosis and treatment drive the market growth.

End-use Insights

Based on end use, the hospital segment led the market with the largest revenue share of 57.35% in 2023, due to its advanced medical infrastructure, high volume of procedures, role in emergency and critical care, comprehensive patient care approach, adoption of technological advancements, and regulatory and reimbursement support. Hospitals have advanced medical infrastructure and state-of-the-art facilities for performing diagnostic and therapeutic procedures. These factors collectively highlight the pivotal role of hospitals in utilizing hemostasis valves for a wide range of medical interventions, ensuring patient safety and improving clinical outcomes.

The ambulatory surgical centers segment are expected to grow at the fastest CAGR of 5.8% during the forecast period, owing to the shift towards minimally invasive procedures, cost-effectiveness and efficiency, patient convenience and accessibility, technological advancements, increasing number of ASCs, and regulatory and reimbursement support. ASCs are becoming integral to the healthcare landscape, offering high-quality, efficient, and patient-friendly alternatives to traditional hospital-based care.Many healthcare systems and insurance providers recognize the cost-efficiency of ASCs and are more willing to reimburse procedures conducted in these settings. This financial support encourages more healthcare providers to adopt ASCs for various medical interventions, including those requiring hemostasis valves.

Regional Insights

North America dominated the hemostasis market with a revenue share of 41.4% in 2023. The region boasts one of the most advanced healthcare systems in the world, equipped with state-of-the-art facilities and cutting-edge medical technologies. This robust infrastructure supports a wide range of complex medical procedures, including those that require hemostasis valves. Hospitals and healthcare centers across the region are well-equipped with the latest medical devices, ensuring high standards of care and efficient patient management. The widespread availability and adoption of advanced medical equipment play a crucial role in the region's dominance in the market.

Europe Hemostasis Valve Market Trends

The hemostasis valve market in Europe is characterized by its advanced healthcare infrastructure, significant burden of cardiovascular diseases, stringent regulatory frameworks, and emphasis on minimally invasive procedures. According to Eurostat, in 2021, Croatia recorded the highest rate of angioplasty procedures at 553 per 100,000 inhabitants. Germany followed closely in second place with 390 procedures, trailed by Latvia at 328, Austria at 324, and Bulgaria at 303. These factors collectively create a dynamic and promising landscape for the market growth in Europe, ensuring its continued growth and development in the coming years.

Asia Pacific Hemostasis Valve Market Trends

The hemostasis valve market in Asia Pacific region is anticipated to witness at a significant CAGR of 7.9% over the forecast period. This growth is driven by the rising prevalence of cardiovascular diseases, expanding healthcare infrastructure, increasing adoption of minimally invasive procedures, technological advancements, and supportive government initiatives. The Annual Report of 2022 on Cardiovascular Health and Diseases in China, published by the National Center for Cardiovascular Diseases, highlights a significant population with risk factors for CVD, with an estimated 330 million patients suffering from CVD. These include 13 million strokes, 245 million hypertension, 11.39 million coronary heart disease, 45.3 million cases of peripheral artery disease, 8.9 million cases of heart failure, 5 million pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, and 2 million congenital heart disease. Governments in countries like China, India, and Japan are investing heavily in expanding healthcare infrastructure. This includes building new hospitals, clinics, and healthcare centers and upgrading existing facilities with modern equipment and technologies. These factors collectively highlight the dynamic and rapidly evolving healthcare landscape in the Asia Pacific region, ensuring sustained demand and robust market growth in the coming years.

Recent Developments

• In June 2023, SYNDEO Medical launched the Rover SA Hemostasis Valve, a cutting-edge, spring-actuated device engineered to enhance the efficacy of interventional procedures. This valve provides precise control and dependable hemostasis, enabling healthcare professionals to conduct procedures more efficiently. Its innovative design includes a proprietary two-seal mechanism, significantly reducing blood loss and optimizing performance

Hemostasis Valve Market Report Scope

Global Hemostasis Valve Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global hemostasis valve market report based on type, application, end-use, and regions.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Hemostasis Valve Y- Connectors

  • Double Y- Connector Hemostasis Valves

  • One- Handed Hemostasis Valves

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Angiography

  • Angioplasty

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait